Clinical and epigenetic aging clocks vs low back pain in NHANES
In this cross-sectional NHANES 1999–2002 analysis, neither routinely measurable clinical aging clocks nor epigenetic clocks were associated with low back pain in the past three months or with physical-function disability. [1]
Automatic summary · not editorially reviewed
The key findings
This was a cross-sectional analysis of NHANES 1999–2002 adults comparing clinical aging clocks with epigenetic clocks for low back pain and disability. [1]
In the DNA-methylation subsample, no aging clock was associated with low back pain in the past three months. [1]
The authors state that aging-clock signals from small, selected cohorts did not generalise to the population. [1]
The source at a glance
- Study type / format
- Cross-sectional analysis of a nationally representative survey (abstract)
- Population / context
- Adults in NHANES 1999–2002, with clock analyses in the DNA-methylation subsample (n = 2,532 with complete data).
- Summary based on
- Study abstract
- Publication status
- Preprint · peer-review status not confirmed
- Original publication
- October 5, 2026
NHANES adults: clinical vs epigenetic clocks
The study asked whether a clinical aging clock measurable at the bedside carries the same signal as epigenetic clocks, and whether either tracks low back pain in an unselected national population. It was a cross-sectional analysis of NHANES 1999–2002 adults, reported following STROBE. Clinical clocks (phenotypic age [PhenoAge] and Klemera–Doubal biological age) came from routine blood chemistry; epigenetic clocks came from the DNA-methylation subsample. Outcomes were self-reported low back pain in the past three months and physical-function disability. The primary contrast was clinical PhenoAge versus its methylation counterpart, DNAm-PhenoAge.
Supporting source [1]
No clock linked to pain or disability
In the DNA-methylation subsample (n = 2,532 with complete clock and covariate data; design-effective n ≈ 1,268), no aging clock was associated with low back pain in the past three months. Adjusted odds ratios per standard deviation ranged from 0.64 to 0.99, and every 95% confidence interval crossed 1 (clinical PhenoAge 0.64, 0.25–1.65; DNAm-PhenoAge 0.84, 0.49–1.42). The same-name pair showed no difference between clinical PhenoAge and DNAm-PhenoAge (ratio of odds ratios 0.80, 0.15–4.25; p = 0.79). No clock was associated with physical-function disability after false discovery rate control. The only nominally significant association was between clinical PhenoAge and the deficit-accumulation frailty index (p = 0.012), described as an expected correlation given shared physiological inputs.
Supporting source [1]
Signals from small cohorts did not generalise
The authors conclude that neither routinely measurable clinical aging clocks nor epigenetic clocks were associated with low back pain or disability, and the two phenotypic-age measures showed no significant difference. The aging-clock signals reported in small, selected cohorts did not generalise to this population. Biological-age acceleration is therefore not described as a bedside risk marker for low back pain, and epigenetic clocks added no value over clinical clocks for this outcome. These are cross-sectional associations, not causal findings. This explainer is based on the abstract only; the full text was not reviewed.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. The analysis is cross-sectional, so associations are not causal. Findings apply to the NHANES 1999–2002 DNA-methylation subsample with complete data.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Karaoğlu AC. · europepmc.org · October 5, 2026